Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

NDORMS researchers identify a subset of immune cells that could be a new therapeutic target to treat inflamed blood vessels in Giant Cell Arteritis (GCA) and other forms of inflammatory vascular disease.

Blood cells

The research, led by Prof Irina Udalova (Kennedy Institute) in collaboration with Prof Raashid Luqmani (Botnar Research Centre) and published in JCI Insight, identified an immature population of neutrophils that accumulates in the blood of GCA patients and attaches to the arterial vessel wall. The researchers found that reactive oxygen species (ROS) released by these neutrophils trigger changes in blood vessel cells, which could represent an early event in the development of inflammatory lesions.

GCA is one of a group of systemic vasculitides that causes inflammation in the large vessels in the head and neck. It is becoming increasingly common in an ageing population and can lead to significant health problems if untreated, including loss of sight.

To understand more about the cause of GCA, Irina's team analysed individual white blood cells in blood samples from GCA patients. They discovered that the main expansion in cell populations in active GCA was in neutrophils. Dr Lihui Wang, the first author on the paper says: "These cells are normally meant to fight microbes. But to do so they produce reactive oxygen species, among other mediators, which could be pathogenic in prolonged inflammatory conditions. Fully mature neutrophils quickly die, but immature neutrophils that in health are confounded to the bone marrow, live for much longer."

Irina continues, "We were excited to see this population of cells expanded in GCA, infiltrated blood vessels and produced large quantities of ROS. It damaged endothelial barrier and led to endothelial leakage. The same immature neutrophils have recently been linked to severe COVID-19, but the mechanisms are unknown. Thus, our discovery may shed light on the vascular pathology observed in COVID-19 as well."

The research was funded by Versus Arthritis and Oxford-Celgene fellowship programme and the Wellcome Trust.

Funded by

Versus Arthritis logo

Wellcome Trust

Similar stories

New centre aims to help companies conduct more efficient trials

Botnar Main Trials

A new clinical therapeutics centre has been set up by the University of Oxford to help life sciences companies identify interventions that have the greatest potential to deliver patient benefit, and so bring down the cost of early phase clinical trials.

Cognitive–behavioural therapy consistently improves quality of life

Main Rehabilitation and self-management Research

A meta-review of the available research into cognitive behavioural therapy reveals it consistently improves health-related quality of life across different medical conditions and demographic populations.

Oxford to collaborate with Janssen to map the cellular landscape of immune mediated disorders

Main Research

The University of Oxford has entered into a strategic collaboration with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson.

Versus Arthritis Foundation Fellowship awarded to Dr Kristina Zec

Awards Main

Dr Kristina Zec has been awarded a Versus Arthritis Foundation Fellowship to investigate the role of products of lipid oxidation produced by synovial macrophages in triggering articular inflammation.

Study reveals the safety of bisphosphonates in chronic kidney disease

Main

The results of an observational study published in JMBR and funded by the Health Technology Assessment Programme shows that bisphosphonate use is associated with a greater risk of chronic kidney disease progression.

WHiTE Four trial results published

Hip Main OCTRU Orthopaedics and trauma Research Trauma

The results of the WHiTE Four clinical trial for the treatment of fragility hip fractures have been published in The Bone and Joint Journal.